OBJECTIVES/HYPOTHESIS: To evaluate the patterns of failure, survival, and functional outcomes for patients treated with transoral robotic surgery (TORS) and compare these results with those from a cohort of patients treated with concurrent chemoradiation (CRT). STUDY DESIGN: Prospective non-randomized case control study. METHODS: Between April 2007 and April 2009, 30 patients with head and neck squamous cell carcinoma were treated with primary TORS and adjuvant therapy as indicated on an institutional review board-approved protocol. Patients were evaluated before treatment, after treatment, and at subsequent 3-month intervals after completing treatment to determine their disease and head and neck-specific functional status using the Performance Status Scale for Head and Neck Cancer and the Functional Oral Intake Score (FOIS). Functional scores were compared to a matched group of head and neck patients treated with primary CRT. RESULTS: The TORS patient population included 73% stage III-IV and 23% nonsmokers. The median follow-up was 20.4 months (range, 12.8-39.6 months). The 18-month locoregional control, distant control, disease-free survival, and overall survival were 91%, 93%, 78%, and 90%, respectively. Compared to the primary CRT group, TORS was associated with better short-term eating ability (72 vs. 43, P = .008), diet (43 vs. 25, P = .01), and FOIS (5.5 vs. 3.3, P < .001) at 2 weeks after completion of treatment. In contrast to TORS patients who returned to baseline, the CRT group continued to have decreased diet (P = .03) and FOIS (P = .02) at 12 months. CONCLUSIONS: Our early experience in treating selected head and neck cancers with TORS is associated with excellent oncologic and functional outcomes that compare favorably to primary CRT.
OBJECTIVES/HYPOTHESIS: To evaluate the patterns of failure, survival, and functional outcomes for patients treated with transoral robotic surgery (TORS) and compare these results with those from a cohort of patients treated with concurrent chemoradiation (CRT). STUDY DESIGN: Prospective non-randomized case control study. METHODS: Between April 2007 and April 2009, 30 patients with head and neck squamous cell carcinoma were treated with primary TORS and adjuvant therapy as indicated on an institutional review board-approved protocol. Patients were evaluated before treatment, after treatment, and at subsequent 3-month intervals after completing treatment to determine their disease and head and neck-specific functional status using the Performance Status Scale for Head and Neck Cancer and the Functional Oral Intake Score (FOIS). Functional scores were compared to a matched group of head and neck patients treated with primary CRT. RESULTS: The TORSpatient population included 73% stage III-IV and 23% nonsmokers. The median follow-up was 20.4 months (range, 12.8-39.6 months). The 18-month locoregional control, distant control, disease-free survival, and overall survival were 91%, 93%, 78%, and 90%, respectively. Compared to the primary CRT group, TORS was associated with better short-term eating ability (72 vs. 43, P = .008), diet (43 vs. 25, P = .01), and FOIS (5.5 vs. 3.3, P < .001) at 2 weeks after completion of treatment. In contrast to TORSpatients who returned to baseline, the CRT group continued to have decreased diet (P = .03) and FOIS (P = .02) at 12 months. CONCLUSIONS: Our early experience in treating selected head and neck cancers with TORS is associated with excellent oncologic and functional outcomes that compare favorably to primary CRT.
Authors: Brett A Miles; Marshall R Posner; Vishal Gupta; Marita S Teng; Richard L Bakst; Mike Yao; Kryzsztof J Misiukiewicz; Raymond L Chai; Sonam Sharma; William H Westra; Seunghee Kim-Schulze; Bheesham Dayal; Stanislaw Sobotka; Andrew G Sikora; Peter M Som; Eric M Genden Journal: Oncologist Date: 2021-03-18
Authors: Vlad C Sandulache; John Hamblin; Syeling Lai; Todd Pezzi; Heath D Skinner; Numan A Khan; Shayan M Dioun; Christine Hartman; Jennifer Kramer; Elizabeth Chiao; Xiaodong Zhou; Jose P Zevallos Journal: Head Neck Date: 2015-07-04 Impact factor: 3.147
Authors: Jennifer R Cracchiolo; Shrujal S Baxi; Luc G Morris; Ian Ganly; Snehal G Patel; Marc A Cohen; Benjamin R Roman Journal: Cancer Date: 2016-03-11 Impact factor: 6.860
Authors: Arun Sharma; Sapna Patel; Fred M Baik; Grant Mathison; Brendan H G Pierce; Samir S Khariwala; Bevan Yueh; Stephen M Schwartz; Eduardo Méndez Journal: JAMA Otolaryngol Head Neck Surg Date: 2016-07-01 Impact factor: 6.223
Authors: John R de Almeida; Ryan Li; J Scott Magnuson; Richard V Smith; Eric Moore; Georges Lawson; Marc Remacle; Ian Ganly; Dennis H Kraus; Marita S Teng; Brett A Miles; Hilliary White; Umamaheswar Duvvuri; Robert L Ferris; Vikas Mehta; Krista Kiyosaki; Edward J Damrose; Steven J Wang; Michael E Kupferman; Yoon Woo Koh; Eric M Genden; F Christopher Holsinger Journal: JAMA Otolaryngol Head Neck Surg Date: 2015-12 Impact factor: 6.223